ECSP055701A - Nuevos derivados de pirimidinamida y el uso de los mismos - Google Patents

Nuevos derivados de pirimidinamida y el uso de los mismos

Info

Publication number
ECSP055701A
ECSP055701A EC2005005701A ECSP055701A ECSP055701A EC SP055701 A ECSP055701 A EC SP055701A EC 2005005701 A EC2005005701 A EC 2005005701A EC SP055701 A ECSP055701 A EC SP055701A EC SP055701 A ECSP055701 A EC SP055701A
Authority
EC
Ecuador
Prior art keywords
disease
pyrimidinamide
same
new derivatives
benzoylaminophenyl
Prior art date
Application number
EC2005005701A
Other languages
English (en)
Inventor
Werner Breitenstein
Pascal Furet
Sandra Jacob
Paul William Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055701A publication Critical patent/ECSP055701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a nuevos derivados de N-(3-benzoilaminofenil)-4-piridil-2-pirimidinamina sustituidos, procesos para la preparación de los mismos, composiciones farmacéuticas que contienen los mismos, el uso de los mismos opcionalmente en combinación con uno o más compuestos farmacéuticamente activos para la terapia de una enfermedad que responde a una inhibición de actividad de quinasa de proteína, especialmente una enfermedad neoplástica, y un método para el tratamiento de tal enfermedad.
EC2005005701A 2002-09-27 2005-03-23 Nuevos derivados de pirimidinamida y el uso de los mismos ECSP055701A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP055701A true ECSP055701A (es) 2005-05-30

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005701A ECSP055701A (es) 2002-09-27 2005-03-23 Nuevos derivados de pirimidinamida y el uso de los mismos

Country Status (23)

Country Link
US (1) US7655669B2 (es)
EP (1) EP1546127B1 (es)
JP (2) JP4463685B2 (es)
KR (2) KR20070098940A (es)
CN (1) CN100404528C (es)
AT (1) ATE369355T1 (es)
AU (1) AU2003270277B2 (es)
BR (1) BR0314797A (es)
CA (1) CA2499822C (es)
DE (1) DE60315479T2 (es)
DK (1) DK1546127T3 (es)
EC (1) ECSP055701A (es)
ES (1) ES2288615T3 (es)
GB (1) GB0222514D0 (es)
MX (1) MXPA05003253A (es)
NO (1) NO20051966L (es)
NZ (1) NZ538930A (es)
PL (1) PL374443A1 (es)
PT (1) PT1546127E (es)
RU (1) RU2378267C2 (es)
SI (1) SI1546127T1 (es)
WO (1) WO2004029038A1 (es)
ZA (1) ZA200502304B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
AP2470A (en) * 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
CN1939910A (zh) 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
ATE525073T1 (de) * 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
PT2068938E (pt) 2006-09-22 2011-03-23 Novartis Ag Optimização do tratamento da leucemia filadélfia positiva com o inibidor de tirosina quinase abl imatinib
BRPI0718677A2 (pt) * 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
KR101122481B1 (ko) * 2007-05-04 2012-02-29 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
MX2010002005A (es) 2007-08-22 2010-03-11 Irm Llc Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
US8293757B2 (en) 2007-08-22 2012-10-23 Irm Llc 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
AU2011263436A1 (en) * 2010-05-11 2012-08-23 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
CN114127065A (zh) * 2019-03-05 2022-03-01 鸿仪有限责任公司 用于治疗神经退行性疾病和癌症的化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087056T3 (es) 1986-01-13 1996-07-16 American Cyanamid Co 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
DE60212836T2 (de) 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
DE602004028511D1 (de) 2003-12-23 2010-09-16 Koninkl Philips Electronics Nv Bestrahlungsverfahren

Also Published As

Publication number Publication date
JP2010043113A (ja) 2010-02-25
HK1080459A1 (en) 2006-04-28
NZ538930A (en) 2008-04-30
EP1546127A1 (en) 2005-06-29
EP1546127B1 (en) 2007-08-08
ZA200502304B (en) 2006-04-26
PL374443A1 (en) 2005-10-17
JP2006508064A (ja) 2006-03-09
JP5178681B2 (ja) 2013-04-10
PT1546127E (pt) 2007-11-07
GB0222514D0 (en) 2002-11-06
DE60315479D1 (de) 2007-09-20
BR0314797A (pt) 2005-07-26
RU2005113153A (ru) 2006-11-10
AU2003270277B2 (en) 2007-08-23
CA2499822C (en) 2012-04-10
JP4463685B2 (ja) 2010-05-19
CN100404528C (zh) 2008-07-23
ES2288615T3 (es) 2008-01-16
SI1546127T1 (sl) 2008-08-31
RU2378267C2 (ru) 2010-01-10
NO20051966L (no) 2005-04-22
ATE369355T1 (de) 2007-08-15
KR20050047128A (ko) 2005-05-19
AU2003270277A1 (en) 2004-04-19
CA2499822A1 (en) 2004-04-08
CN1684951A (zh) 2005-10-19
WO2004029038A1 (en) 2004-04-08
US7655669B2 (en) 2010-02-02
DK1546127T3 (da) 2007-12-10
DE60315479T2 (de) 2008-04-30
US20060142577A1 (en) 2006-06-29
KR20070098940A (ko) 2007-10-05
KR100876055B1 (ko) 2008-12-26
MXPA05003253A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ECSP055525A (es) Inhibidores de cinasas de tirosina
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TW200615266A (en) Organic compounds
DE602004024375D1 (de) Carboxamidderivate
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
UY27740A1 (es) Nuevos compuestos
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
SE0101932D0 (sv) Pharmaceutical combinations
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE60001586D1 (de) Diphenyl-piperidin derivate
SE0102440D0 (sv) New compound
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.